Rapid Build of HIV Related Protective Barriers
Cohort Study on Appropriate Strategies of The Rapid Build of HIV Related Protective Barriers in Yunnan, China
1 other identifier
interventional
600
1 country
2
Brief Summary
The purpose of the study is to screen the optimal intervention strategies to rapid establish the protective barriers against HIV-infection by maximally decreasing the viremia among HIV- infected patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Mar 2019
Typical duration for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 22, 2019
CompletedFirst Posted
Study publicly available on registry
February 25, 2019
CompletedStudy Start
First participant enrolled
March 1, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2021
CompletedFebruary 25, 2019
February 1, 2019
1.8 years
February 22, 2019
February 22, 2019
Conditions
Outcome Measures
Primary Outcomes (1)
Viral suppression of HIV-infected patients
12 months
Secondary Outcomes (1)
Treatment coverage
12 months
Study Arms (3)
routine care group
NO INTERVENTIONMedical institutions will provide patients routine care according to the national program standard.
medicine intervention group
EXPERIMENTALThe dosage of 400 mg EFV will be used in the antiviral therapy.
consolidated intervention group
EXPERIMENTALMedical institutions will provide personal involved intervention strategies as well as the providing of dosage form of 400 mgEFV in their antiviral therapy.
Interventions
Medical institutions will provide personal involved intervention strategies for patients which guided by viral load testing monthly until viral load drop below the detection limit.
The dosage of 400mg EFV will be used in the antiviral therapy.
Eligibility Criteria
You may qualify if:
- HIV-positive participants who received an newly diagnosed HIV infection within the study period
- Having a current residential address inside of pilot site limits
- Eighteen years old or above
- HIV transmission is heterosexual contact
You may not qualify if:
- IDU
- Having severe mental disorder
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Lincang Center for Disease Control and Prevention
Lincang, Yunnan, China
Wenshan Center for Disease Control and Prevention
Wenshan, Yunnan, China
MeSH Terms
Interventions
Study Officials
- PRINCIPAL INVESTIGATOR
Zhao Yan, PHD
National Center for AIDS/STD Control and Prevention
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER GOV
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 22, 2019
First Posted
February 25, 2019
Study Start
March 1, 2019
Primary Completion
December 31, 2020
Study Completion
March 1, 2021
Last Updated
February 25, 2019
Record last verified: 2019-02